Rabia Gurses Ozden - Jul 1, 2022 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role: Chief Medical Officer
Signature: /s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
Stock symbol: OCUL
Transactions as of: Jul 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/15/2022, 08:01 PM
Previous filing: Mar 18, 2022
Next filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUL	Common Stock	Award	$0	+6.67K	+14.63%	$0.00	52.2K	Jul 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+20K		$0.00	20K	Jul 1, 2022	Common Stock	20K	$4.09	Direct	F2
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+20K	+100%	$0.00	40K	Jul 1, 2022	Common Stock	20K	$18.70	Direct	F3
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+10K		$0.00	10K	Jul 14, 2022	Common Stock	10K	$4.30	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 1, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on July 1, 2023, and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2	On July 1, 2022, the reporting person was granted an option to purchase 20,000 shares of the Company's common stock, vesting over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant.
F3	As previously reported, on February 1, 2021, the reporting person was granted an option to purchase 50,000 shares of the Company's common stock. The option vests in four installments based on the Company's satisfaction of certain performance criteria. The performance criteria for the first two installments were met on or prior to December 31, 2021, resulting in the vesting of the option as to 20,000 shares. The performance criteria for the third installment were not met on or prior to March 31, 2022, resulting in the termination of the option as to 10,000 shares. The option was amended by the Company and the reporting person to eliminate the performance criteria for the fourth installment, effective July 1, 2022, such that the fourth installment of the option vests over four years, with 17/48 of the shares underlying the option vesting upon July 1, 2022, and 1/48 of the shares underlying the option vesting monthly thereafter.
F4	On July 14, 2022, the reporting person was granted an option to purchase 10,000 shares of the Company's common stock, vesting over thirty months, with 1/30 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant.